We are international
Donate
• health professionals TEXT SIZE   
Bringing the Experts to You



XIIth International Myeloma Workshop, Day 2, February 27, 2009

  • 07:00-08:00 Current Approaches to Supportive Care in Myeloma – Breakfast Symposium (Sponsored by Celgene)
  • 08:15-10:15 Multiple Myeloma Microenvironment
  • 10:30-12:30 Phase III Studies
  • 13:30-15:00 Phase I/II Studies
  • 13:30-15:00 Clinical - New Agents
  • 13:30-15:00 Clinical - Basic Biology - Research
  • 15:30-17:30 Complete Response As A Marker Of Patient Outcomes (Sponsored by Millennium/Ortho-Biotech)
Complete Program Listing

2009 IMW Friday Sessions

Oral Presentations – Clinical – Phase II/III Studies - I
Lenalidomide, bortezomib, and dexamethasone has notable activity in high-risk frontline myeloma
XIIth International Myeloma Workshop in Washington, DC
Paul Richardson, M.D.
Dana-Farber Cancer Institute
Boston, Massachusetts

Bortezomib, dexamethasone, cyclophosphamide, lenalidomide (VDCR) has high efficacy in frontline myeloma
XIIth International Myeloma Workshop in Washington, DC
Shaji Kumar, M.D.
Mayo Clinic
Rochester, Minnesota

Prolonged therapy improves quality of response, and CR associated with superior outcomes, with VMP
XIIth International Myeloma Workshop in Washington, DC
Jean Luc Harousseau, M.D.
Hôpital Hotel Dieu
Nantes, France

A Phase III Study of VMPT versus VMP in newly diagnosed elderly myeloma patients
XIIth International Myeloma Workshop in Washington, DC
Antonio Palumbo, M.D.
Ospedale Molinette
Torino, Italy

MP versus MPT in elderly myeloma patients: the final outcome of the HOVON 49 study
XIIth International Myeloma Workshop in Washington, DC
Pierre Wijermans, M.D.
University Hospital
Rotterdam, Netherlands

First Analysis of HOVON-65/GMMG-HD4 Randomized Phase III Trial Comparing Bortezomib, Adriamycin, Dexamethasone (PAD) vs VAD as induction treatment prior to High Dose Melphalan (HDM) in patients with multiple myeloma (MM)
XIIth International Myeloma Workshop in Washington, DC
Pieter Sonneveld, M.D.
University Hospital
Rotterdam, Netherlands